-

Thermo Fisher Scientific’s Clinical Research Business Receives ATD Award for Employee Talent Development

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific has been recognized as one of the best in the world for its successful enterprise learning and development programs by the Association for Talent Development (ATD), a global organization that empowers professionals to develop talent in the workplace.

The PPD clinical research business is a recipient of the 2022 ATD BEST Awards, which recognize enterprise-wide success in employee talent development. As a result of effective efforts to attract, develop and retain top talent in the industry, the business was recognized among 72 winners in the 2022 BEST Awards Winners' Circle, which includes small and large private, public and not-for-profit organizations from around the world.

“Our business continues to shape career development for our employees by identifying areas to enhance their knowledge and skills to better serve our customers and to enable colleagues to grow their careers,” said Jay Dixon, senior vice president, quality and enterprise learning, clinical research, Thermo Fisher Scientific. “Through our strategic development programs, we are enhancing our learning culture and providing our colleagues with unique opportunities for growth and success while helping to retain top talent within the industry.”

The ATD BEST Awards celebrate and honor those companies that use talent development as a strategic business tool to deliver results. Employee learning and development at the PPD clinical research business includes leadership and high-potential development, key talent programs, technical skills, and job-specific and soft skills training. One of the key offerings is the Core Professional Skills Program, also referred to as Core Pro, which helps employees develop necessary business skills and increase individual effectiveness in order to provide exceptional customer service.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Contacts

Media:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The PPD clinical research business of Thermo Fisher Scientific has been recognized for its successful enterprise learning and development programs.
Release Versions

Contacts

Media:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific Announces Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on October 15, 2026, to shareholders of record as of September 15, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world h...

Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches

SAN FRANCISCO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that the Applied Biosystems™ RapidINTEL™ Plus Cartridge has received approval from the Federal Bureau of Investigation (FBI) National DNA Index System (NDIS) for use with qualifying forensic crime scene samples. The law enforcement milestone makes Thermo Fisher's Rapid DNA workflow on the RapidHIT ID™ System the first eligible to generate DNA profiles that can be searched against the n...

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2026 before the market opens on Thursday, July 23, 2026, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the “Investors” section of our website, www.thermofish...
Back to Newsroom